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Abstract 
Background Neutropenic enterocolitis (NE) is a serious complication in patients 
receiving intensive chemotherapy for the treatment of onco-haematological diseases. 
Yet, the relative incidence of the disease and its risk factors among patients treated 
with different regimen is not well defined.  
 
Methods The development of NE was analysed in 1223 neutropenic episodes from 
692 onco-hematological patients receiving chemotherapy at the isolation Unit of 
CHUV who signed an informed consent (Swissethics 2017-01975). NE was defined 
by the presence abdominal signs and symptoms during neutropenic fever together 
with bowel wall thickening >4mm in any bowel segment by computed tomography or 
ultrasound. The incidence of NE and risk factors known at hospitalization baseline 
were analysed by using uni- and multivariate regression models according to the 
chemotherapy regimen, including those used for the induction of acute myeloblastic 
(AML) or lymphoblastic (ALL) leukemia and autologous hematopoietic cell 
transplantation (HCT). 
 
Results. A total of 72 episodes of radiologically-proven NE (5.9%) occurred; the 
percentage of NE was 16.3% for AML induction (e.g. HOVON based protocol), 5.6% 
for autologous HCT using the BEAM protocol, 4.8% for ALL induction, 2.9% for AML 
salvage (e.g. CLAG or FLAG +/- idarubicin), 1.9% for autologous HCT using a non-
BEAM protocol (e.g. melphalan) and 1.9% for the other types of chemotherapy 
(Figure 1). In the HCT population, the single independent risk factor for NE was the 
BEAM versus non-BEAM protocol (Odd ratio [OR]=3.40, 95% confidence interval [CI] 
1.14-10.1, P=0.03). In AML patients, independent risk factors for NE included 
induction versus salvage chemotherapy (OR=3.87, CI 1.31-11.4, P=0.01), 
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chemotherapy with amsacrine (OR=2.94, CI 1.40-6.21, P=0.005) and triple 
intrathecal chemotherapy (OR=2.03, CI 1.01-4.08, P=0.048). 
 
Conclusions. Susceptibility to NE is strongly influenced by the type of 
chemotherapy. Patients receiving salvage therapy for AML have a surprisingly low 
rate of NE, possibly due to the concomitant use of G-CSF or an immunomodulaor 
effect of fludarabine or cladribine. Intrathecal chemotherapy has probably not a direct 
effect on NE but reflect the patients with high-risk AML quickly neutropenic or 
presenting a leukemic digestive infiltration.  
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Introduction 
 
Neutropenic enterocolitis (NE) is one of the most serious gastrointestinal 
complications in patients receiving intensive chemotherapy for the treatment of onco-
hematological diseases. It affects about 5% of neutropenic patients with a mortality 
rate ranging from 10-63% (1-3, 6-9, 11, 14) and consists in segmental, stenosing 
inflammation of the gastrointestinal mucosa, particularly the ileum, caecum and 
ascending colon. NE is thought to result from a combined effect of cyto- and neuro-
toxicity of chemotherapeutic agents, neutropenia, coagulation disorders and resident 
bacterial flora (6, 18, 20). Because of its high cellular renewal rate, the 
gastrointestinal mucosa is particularly sensitive to chemotherapeutic agents, and can 
be the site of cytotoxic lesions ranging from simple inflammation to loss of integrity, 
large ischemic necrosis and perforation. Neutropenia renders the mucosa particularly 
prone to bacterial or fungal translocation (11) leading to local infection (e.g. 
peritonitis) and/or bacteremia, sepsis and/or shock. Infections result from 
translocation of the resident flora, whose composition is influenced by antibiotics. 
Most pathogens include gram negative bacteria (Escherichia Coli, Klebsiella 
pneumonia, Pseudomonas aeruginosa and other enterobacteria), gram-positive 
bacteria (Viridians streptococci and enterocococci) (1, 4, 5), as well as fungi (e.g. 
Candida spp) (2, 5, 7, 8). Additional factors can further contribute to the development 
of the disease; thrombocytopenia can lead to hemorrhage and compromise vascular 
supply and active leukemic infiltration can contribute to mucosal damage (1-6, 9, 14). 
 
The diagnosis for NE has long been ill-defined, making it difficult to clinically 
distinguish NE from other abdominal infections (appendicitis, cholecystitis, 
diverticulitis, Clostidium difficile colitis, acute megacolon), local manifestations of 
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malignancy (relapse, local infiltration) or other conditions (graft-versus-host disease 
inflammatory bowel disease, intussusception, obstruction, ischemia). The current 
definition combines clinical and radiological criteria. The clinical criteria remain 
heterogeneous and unspecific, including any symptom suggestive of abdominal 
infection (i.e. diarrhea, nausea or vomiting, abdominal distention and right lower 
quadrant tenderness). The radiological criterion is more specific, considering bowel 
wall thickening >4mm detected by abdominal ultrasound (US) examination or 
computed tomography (CT); this 4mm cutoff is considered a reliable criterion, as 
such thickening is proven very uncommon in non-inflammatory bowel conditions after 
chemotherapy (4, 6, 9-11, 14, 17, 24-28).  
 
The therapeutic guidelines are based on the recommendations of the Infectious 
Diseases Society of America (IDSA 2010). A conservative approach including fluid 
resuscitation, bowel rest, abdominal decompression and parenteral nutrition is 
indicated (1, 2, 4-9, 14). Broad-spectrum intravenous antibiotherapy must be initiated 
after hemocultures are taken and include a monotherapy with carbapenem or 
piperacillin-tazobactam or duotherapy with cefepime plus metronidazole. The 
duration of therapy is of 14 to 21 days, until neutrophil recovery and afebrile 
condition; resistance must be tested and the antibiotics switched when needed (1-6). 
In case of sepsis or sepsis shock, a therapy with amikacine and vancomycine should 
be added. In case of detection of candidemia or remain of febrile and neutropenic 
state despite empirical antibiotherpay for more than 5 days, most clinicians support 
antifungal intravenous therapy with caspofungine or amphotericin B (1, 2, 5, 7, 9). 
Surgery is justified in patients with necrotic or perforated segments of the bowel wall, 
uncontrolled bleeding, or presence of deterioration with uncontrolled sepsis despite 
adequate treatment. In that case, the standard surgical treatment is a two-stage right 
hemi-colectomy with removal of all necrotic segments (1, 4, 5, 9, 14). In high-risk 
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patients, such as those with profound neutropenia (<100/ml), hypotension, 
pneumonia or invasive fungal infection, it is recommended to give granulocyte colony 
stimulating factor (G-CSF), although no clinical study has yet verified the actual 
efficiency of this medication (1-3, 5, 6, 8, 9). In case of adverse outcome, such as 
sepsis or septic shock, a placement in the intensive care unit is supported. 
 
The identification of risk factors of NE largely depends on multiple factors, in 
particular the type of clinical definition and study population. Many studies have used 
heterogeneous populations with different types of underlying disease and 
chemotherapy regimens. Those studies have also suggested that particular 
chemotherapeutic agents, such as cytarabine (2,4-6,9) and etoposide (2,4,5), but 
also anthracyclines (8), such as daunomycine (5, 9) and idarubicin (2, 6, 33), 
cyclophosphamide (2,4,9), gemcitabine (4), 5- florouracil (4), fludarabine and 
vincristine (9), taxanes (4), mitoxantrone (8) and platine (2,4), methotrexate (2,9) or 
carmustine (bis-chloroethylnitrosourea, BCNU, BiCNU), etoposide, cytarabine and 
melphalan (BEAM) protocol (3), are associated with NE. However, it is not clear from 
most studies whether NE directly results from the drug toxicity and/or from other 
drugs administered concomitantly. Prednisone might have an adverse effect because 
of its healing-delay-effect (1, 5, 6, 9). Other factors have been reported to influence 
the risk of NE, such as oncological features (relapse of leukemia, uncontrolled 
cancer, intestinal tumor invasion, previous abdominal surgery), co-morbid conditions 
(preexisting bowel abnormalities such as diverticulitis or polyposis, patient age or 
body max index), or clinical conditions (mucositis, thrombocytopenia or concomitant 
Cl. Difficile infection). Again, the heterogeneity among patients in such studies and 
the absence of multivariate models makes it difficult to determine which factor are 
independently associated with NE (2, 3, 5, 6, 15, 16), high-lightening the need for 
studies using homogeneous groups of patients and/or multivariate models. 
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The goal of this study was to determine the incidence of NE in a selected onco-
hematological population, as well as the determination of risk factors correlated with 
NE in well-defined groups of patients at risk. 
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Methods 
 
Study cohort and design. All adult neutropenic patients hospitalized from January 
2007 to June 2017 in the Isolation Unit of Medicine at CHUV for an active 
malignancy such as acute myeloid or lymphoid leukemias (AML, ALL) or chronic 
myeloid or lymphoid leukemias (CML, CLL), Hodgkin and non-Hodgkin lymphomas 
(HL, NHL), multiple myeloma (MM), myelodysplastic syndrome (MDS) or aplastic 
anemia (AA), undergoing intensive chemotherapy and who signed an informed 
consent for contributing to a clinical research database were included (Swissethics 
2017-01975). Clinical date were retrospectively collected, including demography 
(age, sex, ethnic group, co-morbidities, type of underlying hematologic malignancies, 
BMI, chemotherapeutic protocol) and systematic classification of neutropenic 
enterocolitis (duration and degree of neutropenia, abdominal computerized 
tomodensitometry (CT) documentation). 
 
The unit chemotherapeutic protocol for patients with AML was HOVON, composed of 
cytarabine and idarubicine for the 1st induction, followed by cytarabine and 
daunorubicine for the 2nd induction. If the patient did not show a satisfactory 
hematological response after the first inductions, a salvage chemotherapy with 
clofarabine, fludarabine, cytarabine, G-CSF and idarubicin (FLAG-Ida) or cladribine, 
fludarabine, cytarabine, G-CSF and idarubicine (CLAG-Ida) was administrated. Other 
chemotherapeutic agents were used for patients with specific characteristics, such as 
azacytidine for very high-risk patients (age > 65 years, >30 % bone infiltration and in 
agranulocytosis when diagnosed), amsacrine for elderly, cardiac patients or 
combined with cytarabine in consolidation phases and hydroxacarbamine for 
palliative cases. Patients with lymphomas who were eligible for auto-transplant 
followed the BEAM protocol. Other protocols (non-BEAM) included high-dose 
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melphalan for patients with multiple myeloma or carmustine, etoposide and 
cytarabine (BEM) for relapse in elderly patients with lymphomas. 
 
Definitions. NE was defined by the presence of all of the following criteria: (1) 
clinical signs or symptoms suggestive of abdominal infection (abdominal distention, 
tenderness and pain, diarrhea, vomiting and bloody stool), (2) neutropenic fever 
defined by an absolute neutropenic count (ANC) < 500 x, 106 cells/L), and a 
temperature > 38.0 (axillary) or 38.5 (rectal); (3) bowel wall thickening > 4 mm 
(transversal scan) over more than 30 mm (longitudinal scan) in any segment on 
abdominal CT, in the absence of an alternative diagnosis such as Clostridium 
Difficile, Cytomegalovirus (CMV) associated colitis, graft-versus-host disease (GVHD) 
or other abdominal syndroms. Patients who did not have a CT scan and those who 
had a CT scan showing lesions inconsistent with the aforementioned diagnosis were 
considered as non radiologically-proven NE. 
 
Statistical analysis. Statistical analysis was performed using STATA version 15.1 
software (StataCorp LP, College Station, Texas). Risk factors for NE were assessed 
by using univariate and multivariate regression models, significant risk factors with a 
P-value < 0.05 found on univariate analysis were further exposed to multivariate 
analysis. The normal data were reported in mean with standard deviation while the 
non-Gaussian data were reported as median with IQR.. 
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Results 
 
 
A total of 1223 neutropenic episodes occurred in 692 patients hospitalized during the 
study period (Table 1). The underlying malignancies were AML in 496 (41%) 
episodes, MM in 230 (19%), HL and NHL in 216 (18%), ALL in 136 (11%), MDS in 52 
(4%) and other hematological malignancies (e.g. chronic leukemias or AA) in the 
remaining (93; 8%). Among AML patients, 276 (23%) were undergoing AML 
induction phases (HOVON) and 228 (19%) had a salvage regimen. In 444 (36%) 
HCT patients, 180 (15%) underwent the BEAM protocol and 264 (22%) followed non-
BEAM protocols. The mean age was 52.1 years and the percentage of male was 
61%. Of all co-morbidities, 10% were cardiac, 9% respiratory and 4% neurologic, 7% 
had diabetes, and 4% a chronic renal insufficiency.  
 
A total of 72 episodes of NE (5.9%) occurred in 68 patients; the percentage of NE 
was 16.3% in AML induction, 5.6% in HCT using BEAM protocol, 4.8% in ALL 
induction, 2,9% in AML salvage and 1.9% in autologous HCT in a non-BEAM 
protocol (Figure 1).  
 
In the HCT population, the single factor associated with NE was the BEAM protocol 
(OR = 3.40, CI 1.14-10.13, P = 0.028), compared to non-BEAM protocols. 
 
In the AML population, we demonstrated a significant association between the 
development of NE and AML induction phases (OR = 4.0, CI 1.34-11.89, P = 0.01), 
amsacrine (OR = 2.800, CI 1.31-5-95, P = 0.008) and triple intra-thecal 
chemotherapy (OR = 2.1, CI 1.05-4-30, P = 0.04), compared to salvage 
chemotherapy (Table 2). 
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Discussion 
 
 
In this study, we provide a comprehensive overview of NE in a 10-year retrospective 
cohort of onco-hematological patients. Previous studies, mostly retrospective ones, 
have been limited by several factors, including heterogeneous groups of patients at 
risk and/or failure to use specific radiological criteria (2, 10), and/or a very limited 
number of cases (only one study included >50 cases of NE, but only half of them did 
have a radiologically-proven NE, 26). Prospective studies are also limited to only a 
few cases of the disease (maximum 25 cases of NE; 8-10, 11, 27). Thus, to our 
knowledge, this is the largest study of NE adult patients with a homogenous and 
reliable radiological diagnosis criteria of bowel wall thickening on CT, and the only 
allowing for differential incidence estimates according to the underlying disease and 
chemotherapy regimens. 
 
Overall, we demonstrated an incidence of NE of 5.9% in our population at risk 
(patients hospitalized for hematological malignancies, for high-dose chemotherapy in 
solid tumor or for aplastic anemia), which is consistent with the incidence reported in 
a large review of 21 studies (5.6%, 10). Other studies described incidences varying 
from 3.5 to 6.5% in sample sizes never exceeding more than 500 neutropenic 
episodes (9, 23, 29, 31). We demonstrated that the incidence of NE is very different 
when the radiological criterion is accounted for, emphasizing the importance of 
radiological confirmation for the diagnostic of NE.  
 
Our study clearly illustrates important differences according to the chemotherapy 
regimens, ranging from 16.3% among patients receiving an induction with a 7+3 (i.e 
HOVON) based therapy to only 1.9% in patients receiving non-BEAM chemotherapy 
previous HCT. Among patients undergoing induction chemotherapy for AML, the 
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incidence of NE was 16.3% for those undergoing a 7+3 regimen compared to only 
2.9% in salvage regimen. Other studies described different incidences of NE, varying 
from 2.35% to 15.4% in the acute leukemia population either without lymphoid vs 
myeloid distinction, without any radiological diagnostic criterion of NE or with smaller 
sample sizes (9, 10, 23, 24, 27, 29, 30).  
 
Among patients undergoing autologous HCT, the incidence of NE was 5.6% for 
those undergoing BEAM regimen compared to only 1.9% for those under other 
protocols.  Gil et al. reported an incidence of NE proven by abdominal US of 12% 
among BEAM patients, in a smaller population (N=297) but with more NE cases 
(N=32) (3). Both studies differed by the number of Hodgkin lymphomas (89 in the Gil 
and al study versus 29 patients in our study). This higher number of NE cases may 
be explained by the nature of the Gil and al study, which may have increase the 
number of NE diagnoses by using abdominal US. This is the first study to analyze 
and confirm BEAM as a NE risk factor in HCT population with a CT scan criterion. 
 
Ara-C alone, which plays an important part in the immunosuppression in the protocol, 
had already been described without analysis clarification of chemotherapeutic 
regimens or dosis use (5, 6, 9, 34). Unexpectedly, the incidence of NE was 
dramatically higher among acute leukemia patients receiving the “7+3” protocol 
(16.3%) compared to those receiving FLAG/CLAG salvage (OR = 4.0, CI 1.34-11.89, 
P = 0.01). The difference between these two groups might be a consequence of the 
immunomodulator effect of fludarabine or cladribine, given 4 hours before cytarabine 
infusion, and could be a key in decreasing the inflammatory state of hemato-
oncological patients. Another impact could be the systematical concomitant use of G-
CSF in the salvage regimen, which decreases the entry in agranulocytosis.  
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As for the other risk factors, azacitidine is a regimen used in selected high-risk 
patients that can be prone to NE because of their long hospitalizations. Triple intra-
thecal chemotherapy has probably not a direct effect on NE but could reflect the 
patients with extensive diseases such as those with neurological spread, poorer 
prognosis after genetic risk classification, hyperleucocytosis, rapid agranulocytose or 
uncontrolled cancers that might infiltrate the abdominal layers and be part of the 
pathogenesis of NE. As the pathogenesis of its implication is not yet well-understood 
and no statistical analysis has been done on the subject, further investigations of its 
risks are to be emphasized in the future. 
 
In conclusion, this is a retrospective study made among hemato-oncological patients 
who developed radiologically-confirmed NE, estimating reliable estimates of NE in 
different populations and demonstrating the BEAM and the HOVON protocols as two 
main risk factors of developing the disease. Prospectively, this could help identify 
high-risk groups in the onco-hematological population for an early clinical and 
radiological recognition of NE, as well as adapt strategic prevention, such as oral 
specific prophylactic antibacterial and/or antifungal therapy, combined with early give 
of G-CSF. The consideration of genetic risk classification is to emphasize further in 
the future and could lead to individualized chemotherapeutic treatments, causing less 
secondary adverse effect of the regimens without reducing their efficacy. 
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Figure 1. Percentage of patients with clinical manifestations suggesting of 
neutropenic enterocolitis and those with radiologically-proven neutropenic 
enterocolitis according to the type of chemotherapy at the isolation Unit of 
CHUV (2007-2017). 
 
 
Note: AML: acute myeloid leukemia, HCT: autologous hematopoietic cell transplant, ALL: acute 
lymphoblastic leukemia, BEAM chemotherapy comprises administration of BCNU, etoposide, ARA-C, 
and melphalan; non-BEAM regimen include melphalan (N=223) or other regimen (N=41); salvage 
regimen include fludarabine, cladribine or clofarabine with high dose cytarabine, each administered with 
granulocyte colony stimulating factor (G-CSF) +/- idarubicine. Other chemotherapy regimens include 
those administered for lymphoma, myeloma as well as consolidation courses for AML and ALL. 
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Table 1 : Demographic characteristic of the population 
 
 
 
All episodes 
N= 1223 
NE episodes 
N = 72 
NE in AML  
N = 41 
NE in HCT  
N = 15 
Variable N (%) N (%) N (%) N (%) 
     
Age at cohort entry (mea years; range) 52 (18-75) 54 (18-75) 52 (29-75) 58 (37-68) 
Male sex 746 (61) 43 (60) 25 (61) 9 (60) 
     
Ethnictiy     
Caucasian 1142 (93) 69 (96) 40 (98) 13 (87) 
African
 
42 (3) 2 (3)  2 (13) 
Asian 19 (2)    
South American 17 (1) 1 (1) 1 (2)  
     
Underlying disease     
AML 548 (45) 45 (63) 41 (100) 2 (13) 
MM 230 (19) 3 (4)  3 (20) 
NHL/HL 216 (18) 11 (14)  9 (60) 
ALL 136 (11) 4 (6)   
Other 
1 
93 (8) 9 (13)  1 (7) 
 
    
Comorbidities     
Cardiac  124 (9) 10 (14) 4 (10) 28 (8) 
Respiratory  110 (9) 4 (5) 3 (7) 23 (6) 
Diabetes 82 (7) 4 (5) 1 (2) 26 (7) 
Chronic renal failure 52 (4) 2 (3)  20 (6) 
Neurological 53 (4) 3 (4) 2 (5) 13 (4) 
     
Chemotherapeutic regimens     
HOVON-induction 276 (23) 45 (63) 37 (90)  
AML Salvage 228 (19) 6 (8) 4 (10)  
HCT BEAM 180 (15) 10 (14)  10 (67) 
HCT non-BEAM 264 (22) 5 (7)  5 (33) 
Other chemotherapies
2
 275 (22) 4 (8)   
Note : AML: acute myeloid leukemia ; MM: multiple myeloma; NHL: non-Hodgkin lymphoma; ALL : acute lymphoblastic leukemia; 
MDS: myelodysplastic syndrome; HL : Hodgkin lymphoma; NHL : Non-Hodgkin lymphoma; HCT : hematopoietic cell transplantation; 
HOVON include cytarabine and idarubicine/daunorubicine ; Salvage regimen include fludarabine, cladribine or clofarabine, high dose 
Ara-C, each administered with granulocyte colony stimulating factor (G-CSF) +/- idarubicine; HCT BEAM include  BCNU, etoposide, 
ARA-C, and melphalan; non-BEAM regimen include melphalan or other chemotherapies.  
1
 Other underlying diseases include aplastic anemia (N=6), chronic myeloid (N=28) and lymphoid (N=3) leukemia and others such as 
solid tumors (N= 56)  
2 
Other chemotherapies include those administrated for MM or HL/NHL, ALL inductions or consolidation regimens 
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Table 2. Multivariate analysis of neutropenic enterocolitis episodes in acute 
myeloid leukemia patients 
 
 
  Multivariate 
N=41 
Risk factors  OR (95%CI) P-value 
Chemotherapy    
     Azacitidine  3.960 (0.96-16-38) 0.058 
     Amsacrine  2.800 (1.31-5-95) 0.008 
     Intra-thecal Cytarabine  2.120 (1.05-4-30) 0.036 
     HOVON induction  4.000 (1.34-11-89) 0.013 
Note : HOVON include cytarabine and idarubicine or daunorubicine   
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